Leerink Swann downgraded shares of Epizyme (NASDAQ:EPZM) from an outperform rating to a market perform rating in a research report released on Friday, The Fly reports. Leerink Swann currently has $18.00 target price on the biopharmaceutical company’s stock.
Other research analysts have also recently issued reports about the company. HC Wainwright reiterated a buy rating on shares of Epizyme in a report on Thursday, October 31st. Zacks Investment Research cut Epizyme from a hold rating to a sell rating and set a $11.00 target price for the company. in a research note on Monday, October 21st. Citigroup lifted their target price on Epizyme from $25.00 to $35.00 and gave the company a buy rating in a research report on Thursday, January 23rd. BidaskClub raised Epizyme from a hold rating to a buy rating in a research note on Tuesday, December 31st. Finally, Wedbush reiterated an outperform rating and set a $24.00 price target on shares of Epizyme in a report on Thursday, December 19th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $25.13.
Shares of EPZM stock opened at $21.36 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.90 and a quick ratio of 10.90. The company has a market capitalization of $1.95 billion, a PE ratio of -13.27 and a beta of 2.68. The firm’s 50-day moving average is $22.62 and its two-hundred day moving average is $15.29. Epizyme has a 12 month low of $8.98 and a 12 month high of $27.82.
In related news, insider Shefali Agarwal sold 2,630 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $20.44, for a total transaction of $53,757.20. Following the completion of the transaction, the insider now owns 63,276 shares of the company’s stock, valued at approximately $1,293,361.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert B. Bazemore sold 6,074 shares of Epizyme stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $20.44, for a total transaction of $124,152.56. Following the completion of the sale, the chief executive officer now owns 93,744 shares of the company’s stock, valued at approximately $1,916,127.36. The disclosure for this sale can be found here. Insiders sold a total of 13,549 shares of company stock worth $297,231 over the last three months. Insiders own 16.60% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY grew its stake in shares of Epizyme by 18.3% in the first quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 3,029 shares in the last quarter. FMR LLC boosted its holdings in Epizyme by 0.3% during the 1st quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock valued at $43,169,000 after acquiring an additional 11,759 shares during the period. Bank of New York Mellon Corp grew its position in Epizyme by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 316,862 shares of the biopharmaceutical company’s stock valued at $3,976,000 after acquiring an additional 45,110 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Epizyme in the 2nd quarter valued at about $5,419,000. Finally, Northern Trust Corp grew its position in Epizyme by 7.2% in the 2nd quarter. Northern Trust Corp now owns 796,239 shares of the biopharmaceutical company’s stock valued at $9,992,000 after acquiring an additional 53,806 shares in the last quarter. Institutional investors and hedge funds own 87.04% of the company’s stock.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Read More: What is the S&P/TSX Index?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.